Zotiraciclib HCl - CAS 1354567-82-0

Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9) . It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.

FLT, JAK, Others, CDK

Others, Chromatin/Epigenetic, JAK/STAT signaling, Tyrosine Kinase/Adaptors, Angiogenesis, Cell Cycle/Checkpoint, Stem Cells

1354485

C23H26Cl2N4O

445.388

-20°C

Ice Packs

Small Compound